Thank you for sharing!

Your article was successfully shared with the contacts you provided.

WASHINGTON (AP) — Columbia Laboratories said Monday that U.S. health regulators denied approval of its hormone-based gel designed to prevent premature birth. Shares of the small drugmaker plummeted more than 8 percent on the news.

Dig Deeper


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.